01What the Company Does — In Plain English

Fortress Biotech is not built like a conventional single-product biotechnology company. Its strategy is to search for pharmaceutical assets that have already passed through meaningful scientific or clinical de-risking, acquire or license those assets, and place them inside focused partner companies that can finance, develop, commercialize or ultimately monetize them.

The parent company seeks to benefit through three economic channels: operating and product revenue, appreciation in its equity interests, and recurring dividends, royalties or transaction proceeds generated by partner companies. The result is a decentralized portfolio in which value can be created through product launches, FDA approvals, licensing transactions, acquisitions and sales of transferable regulatory assets.

Fortress’s current model is visible through commercial dermatology partner Journey Medical, the completed sale of Checkpoint Therapeutics, and Cyprium Therapeutics’ sale of a Rare Pediatric Disease Priority Review Voucher for $205 million following the approval of ZYCUBO for Menkes disease.

Arena Signals: The simplest way to understand Fortress is as a biotech business-development and capital-allocation platform. Its core product is not one drug. Its core capability is finding overlooked assets, creating focused companies around them, and retaining multiple ways to participate in the upside.

02Why Now

Fortress has moved from a period dominated by financing risk and development spending into a period in which several years of portfolio construction are producing tangible economic outcomes.

During the last 15 months, Fortress and its partner companies achieved FDA approvals for Emrosi, UNLOXCYT and ZYCUBO. Checkpoint Therapeutics was acquired by Sun Pharma. Cyprium then sold the ZYCUBO Priority Review Voucher for $205 million. In the first quarter of 2026, Fortress reported consolidated net income attributable to common shareholders of $108.4 million, compared with a $12.7 million loss in the prior-year period.

At the same time, Journey Medical’s commercial platform is becoming a larger operating asset. First-quarter 2026 revenue increased 21% to $16.0 million, driven by Emrosi revenue of $6.3 million compared with $2.1 million one year earlier.

Arena Signals: Fortress is at an inflection point because the model has recently demonstrated its ability to convert regulatory progress into cash, earnings and strategic transactions. The next phase is proving that these outcomes can repeat across the portfolio rather than remain a cluster of unusually successful events.

03Investment Thesis

• The business model targets a structural capital shortage. Fortress believes the supply of credible drug candidates substantially exceeds the people and financing available to develop them.
• Fortress enters after part of the highest scientific risk has already been absorbed. Management generally favors clinical-stage, commercial-stage or internationally validated assets over ground-up discovery programs.
• Each asset can produce several layers of value. Fortress may benefit from product revenue, equity appreciation, royalties, dividends, milestones, company sales or regulatory-asset monetizations.
• Recent transactions validate the model. The Checkpoint sale and the $205 million PRV transaction are direct examples of assets progressing from acquisition and development into monetization.
• Journey Medical provides a growing commercial foundation. Emrosi and the broader dermatology portfolio create recurring product revenue that can reduce dependence on external financing and one-time transactions.
• Biotech distress can improve acquisition opportunities. Closed financing windows and strategic retrenchment may force larger or undercapitalized companies to abandon assets that Fortress can acquire on attractive terms.
• The valuation may obscure the underlying pieces. Investors must separately assess Fortress’s cash, ownership interests, royalty rights, marketed products, contingent payments and remaining development portfolio.

04CEO Playbook

The Mission — Bridge Biotech’s Capital Gap

Arena Signals: Fortress begins with the premise that biotechnology’s principal bottleneck is not a shortage of scientific ideas. It is a shortage of specialized teams, capital and operating infrastructure capable of advancing those ideas. Fortress attempts to turn that mismatch into a sourcing advantage.

The Prize — Three Channels of Shareholder Return

Arena Signals: This is the clearest statement of the Fortress model. A traditional biotech must usually commercialize its own product or sell the company. Fortress deliberately constructs several potential routes to value, allowing the parent to participate even when a partner company raises capital independently or an asset is sold before full commercialization.

The Edge — Acquire What Others Leave Behind

Arena Signals: The competitive edge is organizational experience. As other investors become interested in carve-outs and clinical-stage spinouts, Fortress argues that it already has the sourcing network, legal structure and operating history required to execute this strategy repeatedly.

The Proof — Exploit Market Inefficiencies

Arena Signals: Recent outcomes illustrate the theory. Emrosi, UNLOXCYT and ZYCUBO reached FDA approval; Checkpoint was sold; and the ZYCUBO PRV generated $205 million in gross proceeds. These are different monetization paths arising from the same portfolio-building system.

The Next Move — Invest Through the Downturn

Arena Signals: Fortress’s next opportunity may come from the same financing scarcity that harms the rest of small-cap biotech. The company’s challenge is to remain aggressive enough to acquire valuable assets without repeating the industry’s common mistake of expanding beyond its financial capacity.

05CEO Signals Timeline

06Financial Transformation

Arena Signals: The financial profile is shifting from predominantly development-stage losses toward a combination of commercial revenue and episodic monetization gains. Investors should separate recurring operating performance from transaction-driven income when estimating sustainable value.

07Upcoming Catalysts

08News Flow

09The Debate

10Questions for Management

1. After the $205 million PRV sale, what amount of capital is available at Fortress and Cyprium after redemptions, obligations, taxes and transaction costs?
2. How does management prioritize debt reduction, subsidiary funding, new acquisitions and potential shareholder returns?
3. What commercial milestones would indicate that Emrosi is becoming a durable, high-margin growth product rather than benefiting only from initial launch stocking?
4. What percentage of Fortress’s current estimated value comes from recurring product and royalty revenue versus one-time or contingent transaction payments?
5. Which remaining partner-company assets have the clearest path to a transaction, approval or commercial launch over the next 12–24 months?
6. How many new assets can Fortress realistically acquire and support without materially increasing parent-level dilution?
7. What minimum clinical evidence and deal economics are required before Fortress acquires a new program?
8. How does Fortress protect parent shareholders when partner companies raise capital at depressed valuations?
9. What continuing economics does Fortress expect from the Checkpoint transaction, and what milestones could trigger additional value?
10. What would demonstrate that the recent approvals and monetizations represent a repeatable portfolio cycle rather than an unusually concentrated period of success?